Oscar Health, Inc.
NYSEOSCR enters the final stretch before its August 6 Q2 print with shorts entrenched near multi-month highs, a CEO who sold roughly $54 million of stock in a single week, and a stock trading above where most analysts think it belongs. The short position has stabilised this week rather than extended further. Short interest held near 18.9 million shares — 8.3% of the free float…
OSCR cost to borrow surges 188% in one week to 0.60%, driven by short interest climbing 12.7% to 8.3% of free float as stock retreats from 52-week high.
Snapshot as of 6 Aug 2026
A new long-form analysis for OSCR this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumOSCR enters the final stretch before its August 6 Q2 print with shorts entrenched near multi-month highs, a CEO who sold roughly $54 million of stock in a single week, and a stock trading above where most analysts…
OSCR is navigating a tricky post-rally moment — a 12% monthly surge now fading, a CEO who cashed out $100 million near the top, and short sellers quietly adding to positions as the stock retreats. The short interest…
OSCR enters the second week of June having done something most health insurance stocks have failed to do this year — rally 29% in a month — and now faces the question of whether the Street's belated conviction can…
OSCR just reported the quarter, and the numbers tell two different stories depending on where you look. Q1 2026 EPS came in at $2.07, more than double the $1.01 consensus estimate. Revenue of $4.65 billion was a 53%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OSCR — free to start on ORTEX.
Sign up for free →Open OSCR on ORTEX